Infectious disease-focused Vir Biotechnology Inc. launched at the beginning of 2017 with $150m and ex-Biogen CEO George Scangos at its helm, and just 10 months later the start-up says it has accumulated more than $500m to develop drugs and acquire assets – but it's not done raising capital just yet, Chief Financial Officer Howard Horn told Scrip.
San Francisco-based Vir has made several investments in technology to boost its research and development capabilities in infectious diseases as...






